Activation of the erythropoietin receptor (EpoR) after Epo binding is very transient because of the rapid activation of strong downregulation mechanisms that quickly decrease Epo sensitivity of the cells. Among these downregulation mechanisms, receptor internalization and degradation are probably the most efficient. Here, we show that the Epo receptor was rapidly ubiquitinated after ligand stimulation and that the C-terminal part of the Epo receptor was degraded by the proteasomes. Both ubiquitination and receptor degradation by the proteasomes occurred at the cell surface and required Jak2 activation. Moreover, Epo-EpoR complexes were rapidly internalized and targeted to the lysosomes for degradation. Neither Jak2 nor proteasome activities were required for internalization. In contrast, Jak2 activation was necessary for lysosome targeting of the Epo-EpoR complexes. Blocking Jak2 with the tyrphostin AG490 led to some recycling of internalized Epo-Epo receptor complexes to the cell surface. Thus, activated Epo receptors appear to be quickly degraded after ubiquitination by two proteolytic systems that proceed successively ; the proteasomes remove part of the intracellular domain at the cell surface and the lysosomes degrade the remaining part of the receptor-hormone complex. The efficiency of these processes probably explains the short duration of intracellular signaling activated by Epo. The internalization and degradation of ligand-stimulated cytokine receptors have been extensively studied for the growth hormone (GH) receptor and the interleukin 2 (IL-2)
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The kidney-produced hormone erythropoietin (Epo) is the major regulator of red blood cell production. Epo inhibits apoptosis of the late erythroid progenitors and stimulates their proliferation, allowing the completion of their differentiation program 1 . The Epo receptor (EpoR) is a type 1 transmembrane protein that belongs to the cytokine receptor family. It is synthesized as a 62 kDa precursor that is quickly modified by a high mannose glycosylation that increases its molecular mass to 64 kDa. The mature EpoR exhibits a 66 kDa molecular mass and a complex endoglycosydase H-resistant glycosylation pattern 2, 3 . The cell surface expression of the EpoR appears to be tightly controlled by mechanisms that are only partly understood. The EpoR undergoes dimerization and association with the Jak2 effector kinase during its maturation process and Jak2 association with the EpoR is required for EpoR maturation and cell surface expression 4 . Epo binding induces a conformational change in the receptor complex that activates the associated Jak2 kinases leading to the initiation of intracellular signaling. Several intracellular relays are then activated including STAT5, Ras/MAP kinase and PI3-kinase/Akt pathways (see 5 for review). All Epo-dependent responses including proliferation and survival are abrogated when Jak2 activation is disrupted. Simultaneously, mechanisms of down regulation are turned on and they lead to the rapid decrease of Epo responsiveness of the target cells. These mechanisms involve the recruitment of the SHP-1 phosphatase to the receptor 6 and to the Jak2 kinase 7 , the production and receptor association of inhibitor proteins of the Cis/Socs family [8] [9] [10] and the internalization of the receptors 11 . Moreover we have shown that the maturation and cell surface expression of newly synthesized EpoRs are blocked by a mechanism involving the proteasomes during Epo stimulation 12 .
EpoR and the TPO receptor (Mpl) exhibit strong functional similarities. They are homodimeric cytokine receptors that activate Jak2 to initiate intracellular signaling and their main target cells belong to close differentiation lineages. In contrast to Epo, thrombopoietin
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From 4 (TPO) induces long-lasting signaling in target cells and the duration of this signal is required for megakaryocytic differentiation 13 . It has been recently shown that after TPO binding, 65 to 75 % of the TPO-Mpl complexes are internalized and that at least some of the internalized receptors rapidly recycle to the cell surface 14 . Like Tpo-Mpl complexes, Epo-EpoR complexes are rapidly internalized and this process is not dependent on Jak2 11 . However, the fate of the internalized Epo-EpoR complexes has not been examined.
The internalization and degradation of ligand-stimulated cytokine receptors have been extensively studied for the growth hormone (GH) receptor and the interleukin 2 (IL-2)
receptor. As Mpl and the EpoR, the former is a receptor homodimer associated with the tyrosine kinase Jak2 and the latter is composed of at least 5 proteins including two tyrosine kinases of the Jak family; Jak1 and Jak3 and 3 bona fide receptor chains : IL-2R , and . In both cases, endocytosis of the receptors is constitutive although their cognate ligands increase to some extent the rate of receptor disappearance 15, 16 . Endocytosis of the GH receptor occurs through clathrin coated pits and depends on an active ubiquitination system and proteasome activity 17 . The internalized receptor is then routed to the lysosome and degraded together with the hormone. This step also requires the activity of the ubiquitin/proteasome pathway 18 .
In contrast, internalization of the IL-2 receptor complex mainly occurs through clathrinindependent mechanisms involving detergent-resistant membrane domains 19 . In this study, we investigate the mechanisms of Epo and EpoR internalization and degradation. We show that Epo strongly increases the rate of receptor internalization and degradation that involves both proteasomes and lysosomes. Lysosome targeting of Epo and EpoR requires Jak2 activity and not proteasome activity. Moreover, Jak2 activation induces polyubiquitination of the EpoRs leading to the degradation at the cell surface of the Cterminal part of the intracellular domain of the receptor by proteasomes.
Materials and Methods

Reagents and Cells
Highly purified recombinant human Epo (specific activity 120 000 U/mg) was a generous gift from Dr. M. Brandt (Roche Laboratories). The protease inhibitors N-Ac-LeuLeu-norLeucinal (LLnL) and lactacystin were obtained from Calbiochem. Other inhibitors were purchased from Sigma. Anti-EpoR antibodies used in immunoprecipitation experiments (C-236) were produced by immunizing rabbits with a recombinant protein composed of the full intracellular domain of the human EpoR fused to GST. Experiments using various EpoR mutants have shown that these antibodies recognize epitopes included in the first 60 amino acids of the intracellular domain of the EpoR since they immunoprecipitate full length EpoRs and EpoRs truncated after amino acid 310. Anti-GST control antibodies were prepared using the same protocol. Anti-EpoR antibodies from Santa-Cruz (cat. number SC-695) were used for immunoblot analysis. These antibodies (C-20) recognize the last twenty amino acids of the EpoR. Anti-ubiquitin antibodies (cat number PW 8810) and anti-Jak2 antibodies (cat number SC-278) were from were from Affiniti Research Products (Exeter, UK) and Santa-Cruz 6 respectively. Bissulfosuccinimidyl suberate (BS3) was from Pierce. Deglycosylation enzymes and proteinase K were from Roche (Mannheim, Germany). Human UT-7 cells 24 were cultivated in Minimum Essential Medium ( MEM) containing 10 % fetal calf serum complemented with 2 U/ml Epo. Before each experiment, the cells were growth factordeprived by overnight incubation in Iscove Dulbecco's MEM containing 0.1% bovine serum albumin treated with BioRad AG 501 X8 ion exchange resin and 25 µg/ml iron-loaded human transferrin.
Whole cell extracts, Immunoprecipitation and Western blotting.
Whole cell extracts, immunoprecipitations and Western blots were performed as previously described 25 . Extracts from 5x10 5 cells were used in each assay for the Western blot experiments. Western blots were quantified using the ImageJ 1.32 software (NIH) after densitometric scanning of the films.
Epo labeling, Epo binding and Epo internalization studies
Epo labeling using Iodogen and Epo binding were done as previously described 26, 27 .
A saturating 125 I-Epo concentration (1 nM ; 2 U/ml) was used for these experiments in order to suppress the effects of putative modifications of EpoR affinity induced by the different inhibitors used. Non-specific binding, determined using a 250-fold excess of unlabelled Epo, was less than 5 % in each case. All reported data represent specific binding. In most experiments, we performed an acidic wash to separate cell surface bound and internalized Epo. After incubation with 125 I-Epo, the cells were washed twice at 4°C to remove unbound ligand. They were incubated in 0.5 ml of acidic buffer (NaCl 150 mM, sodium acetate 50 mM, pH 3.5) for 3 min at 4 °C. The pH was then adjusted to 7.4 using 1M Tris/ HCl pH 9 and the cell suspension was centrifuged. The radioactivities of the supernatant (cell surface bound 
Cross-linking studies
In order to cross-link 
Results
1-Epo induces the rapid degradation of its receptor
The half life of the cell surface EpoR in the absence of Epo was determined by blocking protein synthesis with cycloheximide and measuring cell surface EpoRs at several time points controlled by Jak2 association 4 . The intracellular pool of Jak2 was not significantly modified by cycloheximide during the incubation in the presence or absence of Epo, showing that the half-life of Jak2 was much longer than that of the EpoR and that disappearance of the mature form of the EpoR was not due to the lack of Jak2. Figure 1B shows that 125 I-Epo was quickly internalized after EpoR binding. However, Epo dissociation from its receptor is also very rapid at 37 °C. In a two-step protocol where
2-Epo and EpoR degradation
Epo is bound at 4°C and internalization triggered by a shift to 37°C after removal of unbound ligand, most 125 I-Epo dissociates from the cell surface before internalization (data not shown).
Thus, to test for Epo degradation after internalization, UT-7 cells were first incubated for 30 min at 37°C with iodinated Epo to accumulate radiolabeled hormone inside the cells and washed to remove free Epo. The cells were resuspended in fresh medium and the appearance of Epo degradation products in the culture medium was tested by TCA precipitation. As 125 I-Epo degradation was inhibited by methylamine but not by lactacystin. Therefore, we conclude that internalized Epo was degraded by the lysosomes and that proteasomes are not involved in Epo degradation.
In striking contrast with Epo, the EpoR was only partially protected by methylamine,
as assessed by Western blot experiments using the C-20 antibody ( Figures 3B and 3C ).
Moreover, as we reported previously 12 
4-Ubiquitination of the EpoR
The involvement of proteasomes in EpoR degradation led us to test for the ubiquitination of the receptors. To this end, UT-7 cells were incubated for 105 min with LLnL and Epo was added to cell samples 10, 30, 60 and 90 min before the end of incubation with
LLnL. Control cells were incubated with LLnL alone for 105 min. Whole cell lysates were analyzed by Western blots using anti-EpoR antibodies ( Figure 5A ). EpoRs immunoprecipitates were also analyzed by Western blots using anti-ubiquitin antibodies.
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To test whether Jak2 activation was required for EpoR ubiquitination, we used the tyrphostin AG490 that has been shown to specifically inhibit Jak2 activity 33 . Figure 6A shows that blocking Jak2 activity nearly completely abolished Epo-induced EpoR The results presented in figure 6C also suggested that 125 I-Epo was not degraded in AG 490-treated cells ; this was confirmed by TCA precipitation experiments : no TCA soluble radioactivity was detected in AG 490-treated cells incubated up to 2 hours with 125 I-Epo (data not shown). Overall, these results strongly suggest that Epo/EpoR complexes were efficiently internalized when Jak2 activity was blocked, but that internalized complexes were not routed to the lysosomes and that a part of them recycled to the plasma membrane.
Discussion
Activation of growth factor receptors by their cognate ligands is followed by desensitization processes that largely contribute to control both amplitude and duration of intracellular signaling. Both parameters have been shown to play key roles in cellular responses to extracellular signals 34, 35 and their deregulation is associated with severe human pathologies including cancer [36] [37] [38] [39] . In contrast to tyrosine kinase receptors such as the EGF receptor whose desensitization mechanisms have been extensively studied (see 40 for a recent In the present paper, we show that Epo binding to its receptor induces ubiquitination, internalization and degradation of the EpoR. Figure 7 summarizes our results and describes the downregulation mechanisms that are turned on by Epo binding to its receptor. In sharp contrast with the GH receptor (GHR) for which internalization is constitutive 16 and GHR degradation is only slightly increased by GH 42 , internalization and degradation of the EpoR are strongly increased by ligand binding. It has been shown previously that EpoRs unable to bind and activate Jak2 were efficiently internalized after Epo binding, suggesting that Jak2 activation was dispensable for EpoR internalization 11 . In agreement with these results, we observed that blocking Jak2 activity did not inhibit Epo-induced EpoR internalization. Since
EpoR ubiquitination was inhibited when Jak2 activity was blocked, we conclude that EpoR ubiquitination is not required for internalization. Overall these results suggest that Epo 
thrombopoietin (TPO) receptor that promptly recycles onto the cell surface 14 . These properties could at least partly explain why intracellular transduction by the TPO receptor is sustained for several hours 13 whereas Epo signaling is of short duration 12 . Prolonged activation of TPO signaling has been shown to be required for megakaryocytic differentiation by maintaining a high level of Erk activation 13 . In contrast, it is suggested that erythroid differentiation could require a decreased level of intracellular signaling. Indeed, it has been reported that activation of Foxo3A 50 and caspases 51 were necessary for terminal erythroid differentiation. These activations are inhibited by intracellular signaling relays such as the phosphatidylinositol 3-kinase pathway which is strongly activated in Epo-stimulated cells and is required for erythroid cell proliferation 41 . Thus, we can propose that decreasing Epo For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
